Endogenous maternal serum preimplantation factor levels in earlyonset preeclamptic pregnancies

Objective: Preimplantation-factor (PIF) is a new peptide with many potential functions. We aimed to compare the maternal serum PIF levels among early-onset preeclamptic patients with the healthy controls at the same gestational age. Patients and Methods: Thirty-nine early-onset preeclamptic (< 34 gestational weeks) patients and 45 healthy expecting women have been added to our study. Patients with or suspicion of any chronical maternal disease, gestational diabetes, twin pregnancies, fetal or placental anomalies or any other obstetric complications have been excluded. Competitive enzyme-linked immunosorbent assay (ELISA) (Elabscience Biotechnology Co., Texas, USA) has been used to analyze the PIF levels in the collected samples. Gestational age, maternal age, gravida, parity, fetal growth, body mass index (BMI), maternal weight and height, plasma PIF levels have been collected/measured and analyzed in both groups. Results: The primary outcome of our study –the Preimplantation Factor- was significantly higher in study group than the healthy controls (100.36 ± 41.92 vs. 83.14 ± 51.27 p=0.016). Conclusions: We have found the PF levels statistically higher in the study group. PIF levels might have a role in the progression and pathogenesis of the preeclamptic patients. Further studies with larger groups have to be planned and performed to resolve the real relation between PIF and preeclampsia.